Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Liabilities: 2011-2024

Historic Total Liabilities for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $2.8 billion.

  • Ptc Therapeutics' Total Liabilities fell 3.35% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 3.35%. This contributed to the annual value of $2.8 billion for FY2024, which is 3.27% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Total Liabilities of $2.8 billion as of FY2024, which was up 3.27% from $2.7 billion recorded in FY2023.
  • Ptc Therapeutics' 5-year Total Liabilities high stood at $2.8 billion for FY2024, and its period low was $1.7 billion during FY2020.
  • In the last 3 years, Ptc Therapeutics' Total Liabilities had a median value of $2.7 billion in 2023 and averaged $2.5 billion.
  • Data for Ptc Therapeutics' Total Liabilities shows a peak YoY soared of 67.69% (in 2020) over the last 5 years.
  • Over the past 5 years, Ptc Therapeutics' Total Liabilities (Yearly) stood at $1.7 billion in 2020, then grew by 12.18% to $1.9 billion in 2021, then climbed by 5.99% to $2.1 billion in 2022, then skyrocketed by 32.23% to $2.7 billion in 2023, then rose by 3.27% to $2.8 billion in 2024.